Welcome to our dedicated page for CIBUS news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on CIBUS stock.
Cibus Inc (CBUS) delivers innovative agricultural solutions through its proprietary gene-editing platform. This news hub provides investors and industry stakeholders with essential updates on technological advancements, strategic partnerships, and operational developments.
Access timely press releases covering key milestones in crop trait development, including herbicide tolerance breakthroughs and disease-resistant varieties. The curated collection features earnings announcements, regulatory filings, and progress reports on sustainable farming initiatives.
Discover updates on Cibus' Rapid Trait Development System (RTDS®) applications and licensing agreements with global seed producers. Content spans product launch details, research collaborations, and intellectual property achievements in agricultural biotechnology.
Bookmark this page for direct access to verified CBUS updates, ensuring informed decision-making about this pioneer in precision plant breeding. Regular updates provide insights into how Cibus' innovations address global food security challenges through advanced genetic solutions.
Cibus has announced a $13.0 million registered direct offering. The company will sell 1,298,040 shares of its Class A Common Stock and warrants to purchase up to 1,298,040 shares at $10.00 per share for institutional investors and $10.20 per share for the CEO, Rory Riggs. The warrants, exercisable immediately, will expire in five years. Gross proceeds from the offering are approximately $13.0 million before expenses. Closing is expected on June 13, 2024. The funds will support the development of new and existing seed traits, Trait Machine operations, and general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent.
Cibus, an agricultural technology company listed on Nasdaq (CBUS), announced its participation in two upcoming investor events in June 2024. Rory Riggs, Co-Founder, CEO, and Chairman, will present at the Stifel Cross Sector Insight Conference in Boston, MA on June 5 at 1:50 p.m. ET. Additionally, both Riggs and Co-Founder, President, and COO Peter Beetham will present at the Bank of America AgTech Conference virtually on June 6 at 3:00 p.m. ET. These events will provide Cibus with the opportunity to connect with investors and discuss its business developments.
Cibus has achieved a major milestone by successfully editing Canola with a third mode of action to resist White Mold (Sclerotinia). This advancement is expected to enhance disease resistance in Canola and potentially other crops like Soybean and various produce. The edited Canola plants will undergo controlled environment testing later this year. Cibus aims to improve crop yields and reduce fungicide use, thereby lowering input costs. This development underscores the company's capability in accelerating the creation of complex gene-edited traits.
Cibus (Nasdaq: CBUS), a leader in agricultural biotechnology, commends the Canadian Food Inspection Agency (CFIA) for updating its feed guidelines to regulate plants developed using gene editing, similar to conventional breeding. The guideline revision is part of a global trend, including the UK and EU, recognizing gene editing technologies like Cibus' RTDS® as safe and equivalent to traditional breeding methods. Cibus' RTDS platform aims to enhance global food productivity and sustainability. These guidelines are important for innovation and investment in Canada's agri-food sector, particularly for crops like canola. Cibus is progressing towards commercializing its Pod Shatter Reduction trait in canola, promising yield protection for Canadian farmers.
Cibus, Inc. (Nasdaq: CBUS) will participate in the BMO Global Farm to Market Conference with a presentation hosted by the CEO and COO on May 16, 2024. The company utilizes gene editing technologies to enhance plant traits in seeds.
Cibus, Inc. (Nasdaq: CBUS) reported Q1 2024 financial results and business update. Key highlights include success in single cell regeneration platform for Wheat, agreements in Rice, advancing Pod Shatter Reduction trait in Canola, and recognition by Fast Company. The PR also mentions global approval momentum for new genomic techniques, regulatory shifts in EU, and appointment of a new Chief Legal Officer, Jason Stokes. Financially, the company reported a cash position of $24.5 million, increased R&D and SG&A expenses, and a net loss of $27.0 million.
FAQ
What is the current stock price of CIBUS (CBUS)?
What is the market cap of CIBUS (CBUS)?
